Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix

Inclusion Criteria: * Pregnant women of ≥18 and ≤ 64 years of age * Nulliparous * Unripe cervix with ≤ 4points according to Bishop/Westin score (0-10 points scale) * Planned for labor induction after 4-7 days of IMP treatment * Examples of diagnosis as a basis for induction: * Post term pregnancy (40-41 weeks of gestation) * Gestational diabetes * Diabetes type 1 - well controlled * Pre-eclampsia (BP diastolic \<100, systolic \<140) * Hypertension - well controlled * Hepatosis (without clinically significantly elevated serum bile acids) * Maternal age ≥ 40 years * Humanitarian-psycho social reasons * Oligohydramnios * Gestational age \> 37 weeks confirmed by ultrasound before 21 weeks of gestation * Singleton pregnancy * Subject is, as per the discretion of the Investigator, able to comply with the requirements of the protocol including an ability to be present at all required controls * Subject can understand and sign an informed form * Provision of written informed consent Exclusion Criteria: * Subjects who are unable to understand the written and verbal instructions in local language * Breech presentation and other abnormal fetal presentations * Previous uterine scar * Spontaneous rupture of membranes at inclusion * Pathologic CTG at inclusion * Fetal estimated weight \> 2SD of normal fetal estimated weight earlier diagnosed by ultrasound and documented in patient record * Mother's BMI \> 35 at early pregnancy * Known IUGR defined as ≤ 2SD of normal * Presence of eclampsia * Severe Pre-eclampsia * HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) * Clinically significant vaginal bleeding in need of hospitalization in the third trimester * Placenta previa * Previously known coagulation disorders (Leiden, heterozygote - OK) * Current use of any drugs that interfere with hemostasis (including heparin /LMWH, direct oral anti-coagulant medication, non-steroidal anti-inflammatory drugs (NSAID) compounds and vitamin K antagonists.) * Current use of acetylsalicylic acid (ASA) compounds or use within the week preceding inclusion * Diagnosed with HIV or Acute hepatitis * Known history of allergy to standard heparin and/or LMWH heparin * History of heparin-induced thrombocytopenia * Current drug or alcohol abuse which in the opinion of the Investigator should preclude participation in the study. * Current participation in other interventional medicinal treatment studies * Subject has a fear of needles which is believed by the Investigator to affect study medication compliance